Patents Assigned to H. Lundbeck A/S
  • Publication number: 20190151309
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., H. LUNDBECK A/S
    Inventors: Kenji MAEDA, Mai NAKAMURA
  • Patent number: 10287261
    Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: May 14, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Heidi Lopez de Diego, Kim Lasse Christensen, Rene Holm, Jens Kateb
  • Patent number: 10258617
    Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: April 16, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Connie Sanchez Morillo, Karina Krøjer Søby, Benny Bang-Andersen
  • Patent number: 10196439
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Patent number: 10195186
    Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Philip James Maltas, Stephen Watson, Morten Langgård, Laurent David
  • Patent number: 10150771
    Abstract: The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 11, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Mikkel Jessing
  • Patent number: 10118907
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 6, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Patent number: 10071963
    Abstract: The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: September 11, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Kristine Birklund Andersen, Michael Harold Rock, Heidi Lopez De Diego, Frans Dennis Therkelsen
  • Patent number: 10058540
    Abstract: The present invention is directed to compounds of Formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 28, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Patent number: 10059669
    Abstract: The present invention is directed to compounds according to Formula (I) which compounds are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for 5 which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 28, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Patent number: 10045974
    Abstract: The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of A? deposits is beneficial such as Alzheimer's disease.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: August 14, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Patent number: 10034874
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladstrom, Christine Persson, Didier Meulien, Per Sorensen, Thomas Jon Jensen, Jette Buch Ostergaard
  • Patent number: 10034861
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 10034876
    Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Svend Treppendahl, Heidi Lopez de Diego
  • Patent number: 10030007
    Abstract: The present invention provides Quinazolin-THF-amines as PDE I inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 24, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • Patent number: 10011606
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 3, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing
  • Patent number: 10011596
    Abstract: The present invention provides compounds of Formula I for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula I.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 3, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Lena Tagmose, Mauro Marigo
  • Publication number: 20180179270
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Publication number: 20180179271
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Patent number: D842452
    Type: Grant
    Filed: July 22, 2017
    Date of Patent: March 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Cara Dignum, Ken Liljegren, Charlotte Miller